文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

静脉-静脉体外膜氧合中附加前列腺素E1治疗:一项随机、双盲、安慰剂对照先导试验

Add-On Prostaglandin E1 in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-Blind, Placebo-controlled Pilot Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论静脉-静脉ECMO患者附加PGE1 5 ng/kg/min未减少红细胞输注率,但血栓栓塞和临床显性出血事件较少,作者认为需更大研究评估。

这项在奥地利维也纳医科大学两个内科ICU进行的随机、双盲、安慰剂对照II期先导试验,纳入接受静脉-静脉ECMO的成人,在标准普通肝素抗凝基础上随机给予静脉输注5 ng/kg/min PGE1或安慰剂(0.9%氯化钠)。主要终点为每ECMO日输注浓缩红细胞率,两组相似(0.41 vs 0.39;P=0.733)。PGE1组血栓栓塞事件较少(7 vs 16;P=0.020)、无血栓栓塞时间较长(HR 0.302;P=0.01),临床显性出血事件较少(2 vs 11;P=0.017)、无出血时间较长(HR 0.213;P=0.047)。作者结论为PGE1附加治疗安全但未达到主要终点,需更大研究评估。

要点

  • 静脉-静脉ECMO成人在标准普通肝素抗凝基础上加用PGE1 5 ng/kg/min静脉输注,每ECMO日浓缩红细胞输注率与安慰剂相似(0.41 vs 0.39;P=0.733),未达主要终点。
  • PGE1组血栓栓塞事件7例 vs 安慰剂组16例(P=0.020),无血栓栓塞时间HR 0.302(P=0.01)。
  • PGE1组临床显性出血事件2例 vs 安慰剂组11例(P=0.017),无出血时间HR 0.213(P=0.047)。
  • COVID-19亚组(n=25)中,临床显性出血HR 0.276(95%CI 0.035-2.186),血栓栓塞HR 0.521(95%CI 0.149-1.825),置信区间均跨1。
  • 作者结论为PGE1附加治疗安全但未减少红细胞输注率,需更大研究评估其在ECMO中的安全性和有效性。

适用人群与场景

  • 接受静脉-静脉ECMO的成人,来自奥地利维也纳医科大学两个内科ICU。
  • 共筛查133例,随机50例,其中48例接受指定研究药物(每组24例)。
  • 研究时间为2016年9月至2021年4月。

处置流程与药物剂量

  • 在标准普通肝素抗凝基础上,随机给予静脉输注5 ng/kg/min PGE1或安慰剂(0.9%氯化钠)。

研究设计与关键结果

  • 研究类型为随机、双盲、安慰剂对照II期先导试验,在两个内科ICU进行,随机50例,48例接受研究药物(每组24例)。
  • 主要终点每ECMO日输注浓缩红细胞率两组相似(0.41 vs 0.39;P=0.733)。
  • PGE1组血栓栓塞事件7例 vs 安慰剂组16例(P=0.020),无血栓栓塞时间HR 0.302(P=0.01)。
  • PGE1组临床显性出血事件2例 vs 安慰剂组11例(P=0.017),无出血时间HR 0.213(P=0.047)。
  • COVID-19亚组(n=25)中,临床显性出血HR 0.276(95%CI 0.035-2.186),血栓栓塞HR 0.521(95%CI 0.149-1.825)。

证据类型、等级与局限

  • 证据类型为随机、双盲、安慰剂对照II期先导试验。
  • 作者结论为PGE1附加治疗安全但未达到主要终点,需更大研究评估其在ECMO中的安全性和有效性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在静脉-静脉ECMO成人中附加PGE1 5 ng/kg/min未减少红细胞输注率,但血栓栓塞和临床显性出血事件较少,需更大研究评估其安全性和有效性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Prostaglandin E1 (alprostadil; PGE1), in addition to low-dose unfractionated heparin, increases the biocompatibility of extracorporeal systems and enhances the efficacy of artificial organs without increasing bleeding risk. Objectives: We investigated the safety and efficacy of PGE1 in adults receiving venovenous extracorporeal membrane oxygenation (ECMO). Methods: This study was a randomized, double-blind, placebo-controlled phase II pilot trial at two medical intensive care units at the Medical University of Vienna, Austria. Adults with venovenous ECMO were randomly assigned to receive an intravenous infusion of 5 ng/kg/min PGE1 or placebo (0.9% saline) in addition to standard anticoagulation with unfractionated heparin. Measurements and Main Results: The primary outcome was the rate of transfused packed red blood cells per ECMO day. Secondary outcomes were the incidence of and time to clinically overt bleeding and thromboembolic events. A post hoc subgroup analysis included only patients with coronavirus disease (COVID-19). Between September 2016 and April 2021, of 133 screened patients, 50 patients were randomized, of whom 48 received the assigned study medication (24 per group). The transfusion rate was similar between groups (0.41 vs. 0.39; P = 0.733). PGE1 was associated with fewer thromboembolic events (7 vs. 16; P = 0.020) and longer thromboembolism-free time (hazard ratio [HR], 0.302; P = 0.01), fewer clinically overt bleeding events (2 vs. 11; P = 0.017), and longer bleeding-free time (HR, 0.213; P = 0.047). In patients with COVID-19 (n = 25), the HRs for clinically overt bleeding and thromboembolism were 0.276 (95% confidence interval, 0.035-2.186) and 0.521 (95% confidence interval, 0.149-1.825), respectively. Conclusions: Add-on treatment with PGE1 was safe but did not meet the primary endpoint of reducing the rate of red blood cell transfusions in patients receiving venovenous ECMO. Larger studies need to evaluate the safety and efficacy of additional PGE1 in ECMO. Clinical trial registered with EudraCT (2015-005014-30) and www.clinicaltrials.gov (NCT02895373).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Buchtele N, Schörgenhofer C, Schwameis M, et al. Add-On Prostaglandin E1 in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-Blind, Placebo-controlled Pilot Trial. Am J Respir Crit Care Med. 2022. PMID: 35426776. doi:10.1164/rccm.202110-2359OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。